MTVA Stock Forecast & Price Target

MetaVia is viewed positively because all active patients in the Part 3a and 3b cohorts reached the highest target doses of 48 mg and 64 mg, showing disciplined titration and suggesting DA-1726 can achieve higher exposure without an obvious early tolerability ceiling. The company’s thesis is strengthened by the possibility of deeper 16-week weight loss, meaningful incremental efficacy at 64 mg versus 48 mg, and manageable gastrointestinal burden, with recent EASL and ADA updates supporting the differentiation narrative through waist circumference reduction and early liver-related signals. Even so, the fundamental case remains execution-dependent, since the more important 4Q26 topline readout must still confirm durable efficacy and tolerability in a crowded incretin landscape.

MetaVia is a high-risk, precommercial biotech whose valuation depends almost entirely on two early-stage assets, with DA-1726 in obesity and DA-1241 in MASH assigned only 20% and 30% probability of success, respectively, under a 13% discount rate. The investment case is vulnerable to multiple execution risks, including disappointing Phase 1 data, uncertainty around finding a MASH combination partner, intellectual property opposition, and the possibility that development or commercialization slip materially versus Street expectations. Financially, the company remains loss-making, posting a $3.8 million net loss in 1Q26, while cash and cash equivalents of $13.7 million as of March 31, 2026 may prove insufficient if R&D and G&A spending continue without a meaningful funding solution.